Adverum Biotechnologies (ADVM) Total Assets by Year
Adverum Biotechnologies, Inc. closed fiscal year 2024 with $179.8M in total assets, $109.1M in total liabilities and $70.7M in shareholder equity. Total assets rose 15.5% from the prior fiscal year. The table below carries 13 fiscal years, from 2012 to 2024, and the quarters Adverum Biotechnologies, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ADVM Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing | FY14Filing | FY13Filing | FY12Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $179.8M+15.5% | $155.8M-49.5% | $308.4M-29.9% | $439.7M-8.9% | $482.6M+116.7% | $222.7M+4.3% | $213.5M+5.7% | $201.9M-13.9% | $234.6M-11.3% | $264.3M+63.3% | $161.9M+14822.2% | $1.1M | N/A |
| Total Liabilities | $109.1M+23.2% | $88.5M-30.2% | $126.9M+2.7% | $123.5M+156.2% | $48.2M+0.9% | $47.8M+287.5% | $12.3M-31.0% | $17.9M-5.8% | $19.0M+61.9% | $11.7M-5.6% | $12.4M+33.7% | $9.3M | N/A |
| Total Equity | $70.7M+5.2% | $67.2M-60.5% | $170.2M-46.2% | $316.2M-27.2% | $434.3M+148.3% | $175.0M-13.0% | $201.2M+9.3% | $184.0M-14.6% | $215.6M-14.6% | $252.6M+69.0% | $149.5Mn/m | -$8.2Mn/m | -$3.5M |
ADVM Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $72.4M-65.6% | $96.2M-58.1% | $137.7M-45.1% | $179.8M+15.5% | $210.2M+17.1% | $229.6M+2.3% | $250.5M-0.8% | $155.8M-49.5% | $179.6M-46.0% | $224.4M-40.2% | $252.7M-38.0% | $308.4M-29.9% |
| Total Liabilities | $128.1M+25.6% | $116.4M+26.2% | $111.2M+28.1% | $109.1M+23.2% | $102.0M+10.4% | $92.2M-14.7% | $86.9M-20.2% | $88.5M-30.2% | $92.4M-25.5% | $108.1M-17.3% | $108.8M-12.5% | $126.9M+2.7% |
| Total Equity | -$55.7M-151.4% | -$20.2M-114.7% | $26.4M-83.9% | $70.7M+5.2% | $108.3M+24.1% | $137.4M+18.2% | $163.7M+13.8% | $67.2M-60.5% | $87.3M-58.1% | $116.2M-52.4% | $143.8M-49.2% | $170.2M-46.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Adverum Biotechnologies, Inc. financials
Frequently Asked Questions
Adverum Biotechnologies, Inc. closed fiscal year 2024 with $179.8M in total assets, $109.1M in total liabilities and $70.7M in shareholder equity.
Adverum Biotechnologies, Inc. (ADVM) total assets rose by 15.5% year over year, from $155.8M to $179.8M in fiscal year 2024.
Adverum Biotechnologies, Inc. (ADVM) reported $72.4M in total assets in Q3 2025. This represents a decrease of 65.6% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Adverum Biotechnologies, Inc. (ADVM) reported on that line in every period on record.